Filing Flows › Prime Medicine (PRME) › Q1 2025
Prime Medicine (PRME) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Prime Medicine (PRME) reported revenue of $1.5M for the first quarter 2025 (Q1 2025), +146% from a year earlier and -33% from the quarter before.
Prime Medicine, Q1 2025: revenue $1.5M (+146% year over year), net loss $51.9M, operating cash flow −$48.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | -33% | +146% |
| Operating profit | −$52.4M | — | — |
| Net earnings | −$51.9M | — | — |
| Operating cash flow | −$48.9M | -401% | — |
What changed
Revenue was $1.5M in Q1 2025, up 146% year over year and down 33% from the previous quarter.
Operating costs exceeded revenue by $52.4M, an operating margin of -3603.3%. Total costs grew 10% against revenue growth of 146%. The fastest-growing cost line was General & admin (+19%). The quarter ended with a net loss of $51.9M, wider than the previous quarter's $42.3M loss.
Operating cash flow was −$48.9M. Non-cash charges added back $1.7M of depreciation and amortization and $5.7M of share-based compensation. Working capital and other items used $4.3M. Capital expenditures of $2.4M exceeded it, leaving free cash flow of −$51.3M.
Questions
What was Prime Medicine's revenue in the first quarter 2025?
Prime Medicine (PRME) reported revenue of $1.5M for the first quarter 2025 (Q1 2025), +146% from a year earlier and -33% from the quarter before.
Source: Prime Medicine 10-Q on SEC EDGAR.